$12.43 0.1 0.8%
Last Trade - 08/03/21
| Market Cap | £698.0m |
| Enterprise Value | £685.3m |
| Revenue | £33.7m |
| Position in Universe | 2807th / 6647 |
| Industry | Market | |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
| Year End 30th Sep | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021E | 2022E | CAGR / Avg | |
|---|---|---|---|---|---|---|---|---|---|---|
| 32.6 | 22.1 | 13.7 | 15.9 | 31.8 | 42.6 | 59.9 | 72.7 | +5.5% | ||
| +78.3 | -69.9 | |||||||||
|
x
|
||||||||||
| Profitability | ||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
| Cashflow | ||||||||||
| Dividends | ||||||||||
| Balance Sheet | ||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing % | |||
| Net Gearing % | |||
| Cash / Assets % |
| Liquidity (ttm) | ||
|---|---|---|
| Curr. Ratio | ||
| Quick Ratio | ||
| Interest Cov. | ||
| Efficiency (ttm) | ||
|---|---|---|
| Asset Turnover | ||
| Recs Turnover | ||
| Stock Turnover | ||
| Latest interim period vs. prior period | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
| 3yr Compound Annual Growth Rate | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
Revenue
Net Income
Normalised EPS
PE Ratio Range
Dividend Yield Range
|
Price Target:
( below Price)
|
31st Dec 2021
|
31st Dec 2022
|
||||
|---|---|---|---|---|---|---|
| Est. Long Term Growth Rate: |
Net Profit () |
EPS () |
DPS () |
Net Profit () |
EPS () |
DPS () |
| Consensus Estimate | ||||||
| 1m Change | ||||||
| 3m Change | ||||||
Veru Inc. is an oncology and urology biopharmaceutical company with a focus on developing medicines for the management of prostate cancer. The Company operates in two segments: Commercial and Research, and Development. The Commercial segment consists of FC2. The Research and Development segment consists of multiple drug products under clinical development for oncology and urology. The Company's prostate cancer pipeline includes VERU-111, VERU-100 and Zuclomiphene Citrate. VERU-111 is an oral chemical entity that targets, crosslinks, and disrupts alpha and beta tubulin subunits of microtubules. VERU-100 is a peptide formulation designed to address the limitations of commercially available androgen deprivation therapies (ADT) for advanced prostate cancer. The Company's commercial products include FC2 Female Condom/FC2 Internal Condom (FC2), a product for the protection against unintended pregnancy and sexually transmitted infections.
| Last Annual | September 30th, 2020 |
| Last Interim | December 31st, 2020 |
| Incorporated | February 4, 1971 |
| Public Since | July 19, 1990 |
| No. of Shareholders: | n/a |
| No. of Employees: | 339 |
| Sector | Consumer Defensives |
| Industry | Personal & Household Products & Services |
| Index | Nasdaq Composite , |
| Exchange | NASDAQ Capital Market |
| Shares in Issue | 78,358,516 |
| Free Float | (0.0%) |
| Eligible for |
ISAs
SIPPs
|
| Address | 48 NW 25th St Ste 102, MIAMI, 33127-4442, United States |
| Web | https://verupharma.com/ |
| Phone | +1 312 5959123 |
| Contact | () |
| Auditors | RSM US LLP |
As of 08/03/21, shares in Veru Inc are trading at $12.43, giving the company a market capitalisation of £698.0m. This share price information is delayed by 15 minutes.
Shares in Veru Inc are currently trading at $12.43 and the price has moved by 0.215k% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Veru Inc price has moved by 0.149k% over the past year.
Of the analysts with advisory recommendations for Veru Inc, there are there are currently 1 "buy" , 0 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Veru Inc is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Veru Inc is scheduled to issue upcoming financial results on the following dates:
Veru Inc does not currently pay a dividend.
Veru Inc does not currently pay a dividend.
Veru Inc does not currently pay a dividend.
To buy shares in Veru Inc you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
Shares in Veru Inc are currently trading at $12.43, giving the company a market capitalisation of £698.0m.
Here are the trading details for Veru Inc:
Based on an overall assessment of its quality, value and momentum, Veru Inc is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Shares in Veru Inc are currently priced at $12.43. At that level they are trading at 0.101% discount to the analyst consensus target price of 0.00.
Analysts covering Veru Inc currently have a consensus Earnings Per Share (EPS) forecast of 0.023 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Veru Inc. Over the past six months, the relative strength of its shares against the market has been 0.305k%. At the current price of $12.43, shares in Veru Inc are trading at 0.128k% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
We were not able to find PE ratio data for Veru Inc.
Veru Inc's management team is headed by:
Here are the top five shareholders of Veru Inc based on the size of their shareholding:
